Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinically significant estimated glomerular filtration rate decline is common in patients receiving immune checkpoint inhibitors: implications for long-term cancer survivors

Donald F. Chute, Sophia Zhao, View ORCID ProfileIan A. Strohbehn, Nifasha Rusimbayala, View ORCID ProfileHarish Seethapathy, Meghan Lee, View ORCID ProfileLeyre Zubiri, Shruti Gupta, View ORCID ProfileDavid E. Leaf, View ORCID ProfileOsama Rahma, View ORCID ProfileZsofia D. Drobni, View ORCID ProfileTomas G. Neilan, View ORCID ProfileKerry L. Reynolds, View ORCID ProfileMeghan E. Sise
doi: https://doi.org/10.1101/2020.12.18.20248471
Donald F. Chute
1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophia Zhao
1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian A. Strohbehn
1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ian A. Strohbehn
Nifasha Rusimbayala
1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harish Seethapathy
1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Harish Seethapathy
Meghan Lee
1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leyre Zubiri
2Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Leyre Zubiri
Shruti Gupta
3Department of Medidicine, Renal Division of Medicine, Brigham and Women’s Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David E. Leaf
3Department of Medidicine, Renal Division of Medicine, Brigham and Women’s Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David E. Leaf
Osama Rahma
4Division of Hematology and Oncology, Dana Farber Cancer Institute, Boston, MAX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Osama Rahma
Zsofia D. Drobni
5Cardiovascular Imaging Research Center(CIRC), Department of Radiology and Division of Cardiology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zsofia D. Drobni
Tomas G. Neilan
6Department of Medicine, Division of Cardiology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomas G. Neilan
Kerry L. Reynolds
2Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kerry L. Reynolds
Meghan E. Sise
1Department of Medicine, Division of Nephrology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Meghan E. Sise
  • For correspondence: msise@partners.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Purpose Immune checkpoint inhibitors (ICIs) are now indicated in more than one in three cancer patients. Acute kidney injury has emerged as an important complication of ICIs; however, there are no studies characterizing the long-term effects of ICIs on kidney function.

Methods Retrospective cohort study of consecutive adult cancer patients treated with ICIs between 2010–2018 at two major cancer centers. The primary aim was to determine the composite outcome of incident or progressive CKD, defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m2 or a ≥30% decline in eGFR sustained >90 days among patients surviving ≥1 year. The secondary objective was to determine the proportion of patients experiencing rapid eGFR decline defined as >3mL/min/1.73m2 per year decline.

Results A total of 5004 adult patients with cancer (mean [SD] age, 64 [13] years; 2699 [54%] male; 4529 [91%] White non-Hispanic) were included, and 2563 surviving ≥1 year were analyzed. During a median follow-up of 688 days (interquartile range, 496 to 1031), the overall event rate of the primary composite outcome was 17% and 20% at 3 and 5 years, respectively. Fine-Gray subdistribution multivariable hazard mode demonstrated that age and coronary artery disease were each independently associated with the primary outcome, adjusted HR (95% CI) 1.12 (1.06, 1.19) per 5 years and 1.27 (1.00-1.62), p < 0.001 and p=0.49, respectively.

Conclusion New onset CKD or 30% eGFR decline is common in patients receiving ICIs who survive ≥1 year. As ICIs are increasingly used in earlier stage cancers, the impact of long term kidney function decline among survivors is extremely important. Additional studies are needed to determine the risk factors and potential modifiers for eGFR decline among patients receiving ICIs.

Competing Interest Statement

Financial disclosures: LZ serves as a consultant for Merck. Dr. Neilan has been a consultant to and received fees from Parexel Imaging, Intrinsic Imaging, H3-Biomedicine, and AbbVie, outside of the current work. Dr. Neilan also reports consultant fees from Bristol Myers Squibb for a Scientific Advisory Board focused on myocarditis related to immune checkpoint inhibitors.

Clinical Trial

n/a

Funding Statement

Dr. Sise is supported by National Institutes of Health (NIH) K23 DK 117014 and the Claflin Distinguished Scholars Award. The NIH had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. TGN is suppored by (NIH) R01HL137562-, R01HL130539, and K24HL150238, and in part, through a kind gift from A. Curtis Greer and Pamela Kohlberg.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Mass General Brigham IRB 857-282-1900 irb{at}partners.org IRB Protocol #: 2017P000501 Our IRB approved this study and waived the need for consent.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

De-identified data can be made available upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted December 22, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinically significant estimated glomerular filtration rate decline is common in patients receiving immune checkpoint inhibitors: implications for long-term cancer survivors
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinically significant estimated glomerular filtration rate decline is common in patients receiving immune checkpoint inhibitors: implications for long-term cancer survivors
Donald F. Chute, Sophia Zhao, Ian A. Strohbehn, Nifasha Rusimbayala, Harish Seethapathy, Meghan Lee, Leyre Zubiri, Shruti Gupta, David E. Leaf, Osama Rahma, Zsofia D. Drobni, Tomas G. Neilan, Kerry L. Reynolds, Meghan E. Sise
medRxiv 2020.12.18.20248471; doi: https://doi.org/10.1101/2020.12.18.20248471
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Clinically significant estimated glomerular filtration rate decline is common in patients receiving immune checkpoint inhibitors: implications for long-term cancer survivors
Donald F. Chute, Sophia Zhao, Ian A. Strohbehn, Nifasha Rusimbayala, Harish Seethapathy, Meghan Lee, Leyre Zubiri, Shruti Gupta, David E. Leaf, Osama Rahma, Zsofia D. Drobni, Tomas G. Neilan, Kerry L. Reynolds, Meghan E. Sise
medRxiv 2020.12.18.20248471; doi: https://doi.org/10.1101/2020.12.18.20248471

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Nephrology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (144)
  • Anesthesia (47)
  • Cardiovascular Medicine (419)
  • Dentistry and Oral Medicine (72)
  • Dermatology (49)
  • Emergency Medicine (147)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (174)
  • Epidemiology (4906)
  • Forensic Medicine (3)
  • Gastroenterology (185)
  • Genetic and Genomic Medicine (689)
  • Geriatric Medicine (72)
  • Health Economics (193)
  • Health Informatics (636)
  • Health Policy (322)
  • Health Systems and Quality Improvement (209)
  • Hematology (86)
  • HIV/AIDS (157)
  • Infectious Diseases (except HIV/AIDS) (5408)
  • Intensive Care and Critical Care Medicine (333)
  • Medical Education (96)
  • Medical Ethics (24)
  • Nephrology (77)
  • Neurology (692)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (128)
  • Occupational and Environmental Health (211)
  • Oncology (447)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (91)
  • Pain Medicine (37)
  • Palliative Medicine (18)
  • Pathology (131)
  • Pediatrics (201)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (88)
  • Psychiatry and Clinical Psychology (787)
  • Public and Global Health (1832)
  • Radiology and Imaging (328)
  • Rehabilitation Medicine and Physical Therapy (142)
  • Respiratory Medicine (257)
  • Rheumatology (87)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (63)
  • Surgery (102)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (38)